nipah
viru
hendra
viru
emerg
highli
pathogen
zoonot
paramyxovirus
belong
genu
henipaviru
infect
human
well
numer
mammalian
speci
virus
use
cell
entri
receptor
follow
initi
entri
organ
capabl
rapid
spread
throughout
host
previous
report
nipah
viru
use
anoth
attach
receptor
differ
entri
receptor
bind
nonpermiss
circul
leukocyt
therebi
promot
viral
dissemin
within
host
attach
molecul
identifi
heparan
sulfat
nipah
viru
hendra
viru
cell
devoid
heparan
sulfat
abl
mediat
henipaviru
transinfect
show
reduc
permiss
infect
viru
pseudotyp
nipah
viru
glycoprotein
bound
heparan
sulfat
heparin
glycosaminoglycan
surfac
plasmon
reson
assay
furthermor
heparin
abl
inhibit
interact
virus
heparan
sulfat
block
cellmedi
transinfect
henipavirus
moreov
heparin
shown
bind
restrain
infect
permiss
cell
vitro
consequ
treatment
heparin
devoid
anticoagul
activ
improv
surviv
nipah
virusinfect
hamster
altogeth
result
reveal
heparan
sulfat
new
attach
receptor
henipavirus
potenti
therapeut
target
develop
novel
approach
highli
lethal
infect
open
novel
perspect
develop
heparan
sulfatetarget
therapeut
approach
emerg
infect
requir
cellmedi
transinfect
proteoglycan
use
sever
virus
bind
target
cell
investig
potenti
role
henipaviru
attach
receptor
heparan
sulfat
hs
complex
sulfat
polysaccharid
glycosaminoglycan
gag
famili
link
ubiquit
core
protein
cell
surfac
extracellular
matrix
eukaryot
hs
compos
repetit
dglucuron
acid
nacetyldglucosamin
disaccharid
motif
modifi
addit
sulfat
group
hs
abil
bind
vast
repertoir
protein
involv
mani
physiolog
well
patholog
process
addit
long
carbohydr
chain
hs
provid
easili
access
bind
site
wide
rang
pathogen
includ
virus
bacteria
parasit
commerci
heparin
hp
wide
use
anticoagul
properti
gag
chemic
relat
hs
display
proteinbind
properti
similar
hs
studi
show
niv
hev
use
hs
attach
receptor
mediat
transinfect
addit
hs
facilit
henipaviru
infect
ci
heparin
compet
hs
bind
viru
therebi
limit
transinfect
infect
final
heparin
significantli
reduc
niv
infect
hamster
suggest
potenti
use
treat
henipaviru
infect
first
ask
whether
leukocyt
could
captur
hev
transmit
suscept
cell
tran
without
becom
infect
fig
previous
found
niv
peripher
blood
lymphocyt
pbl
also
transmit
cellattach
hev
suscept
cell
indic
transinfect
mechan
share
member
henipaviru
genu
transinfect
leukocyt
also
mimick
cho
cell
resist
henipaviru
infect
due
lack
entri
receptor
treatment
cell
heparinas
inhibit
transinfect
properti
accordingli
choderiv
cell
line
lack
express
hs
defici
gag
biosynthesi
enzym
also
highli
defici
abil
mediat
transinfect
niv
fig
character
nivgag
interact
compar
abil
viru
particl
pseudotyp
niv
g
f
glycoprotein
vesicular
stomat
viru
gprotein
vsvg
bind
surfac
coat
hs
analog
heparin
use
surfac
plasmon
reson
spr
strong
hyperbol
associ
shape
observ
inject
phase
sensorgram
niv
vsv
pseudoparticul
clearli
indic
much
stronger
bind
affin
nivpseudotyp
viral
particl
fig
underlin
import
niv
glycoprotein
analyz
interact
assess
specif
nivgag
interact
toward
hs
use
spr
compar
bind
nivpseudotyp
viru
surfac
display
hs
hp
dermatan
sulfat
ds
anoth
sulfat
gag
fig
although
nivpseudotyp
viru
effici
bound
hp
hs
detect
interact
either
niv
hev
wash
cultur
h
transfer
vero
cell
monolay
use
determin
viral
titer
day
cocultur
use
infecti
center
assay
b
cell
treat
heparinas
three
hsdefici
cho
line
incub
niv
analyz
capac
transmit
infect
suscept
vero
cell
tran
result
express
percentag
inhibit
compar
result
untreat
cell
sd
p
p
mannwhitney
u
test
c
spr
analysi
bind
mlv
pseudotyp
either
vsvg
green
niv
glycoprotein
g
f
red
hpactiv
sensor
chip
surfac
spr
analysi
bind
niv
g
f
pseudoparticl
surfac
activ
either
hs
blue
ds
green
hp
red
bind
respons
ru
record
function
time
result
experi
present
ds
surfac
suggest
implic
specif
carbohydr
featur
altogeth
result
suggest
niv
could
specif
use
hs
attach
receptor
promot
effici
transinfect
heparin
competit
inhibitor
henipaviru
transinfect
nivpseudotyp
viru
bind
heparin
addit
hs
fig
next
analyz
effect
heparin
abil
pbl
mediat
niv
transinfect
heparin
reduc
transinfect
properti
pbl
cell
respect
fig
strikingli
heparin
also
activ
appli
contact
viru
pretreat
posttreat
heparin
effect
inhibit
human
pblmediat
transinfect
either
niv
hev
fig
inhibit
reflect
known
capac
heparin
bind
multipl
cell
surfac
protein
due
high
neg
charg
furthermor
pretreat
regimen
heparin
also
transinfect
vero
cell
determin
describ
fig
result
express
percentag
inhibit
compar
result
untreat
cell
sd
p
p
p
mannwhitney
u
test
c
analysi
niv
bind
hsdefici
cell
pretreat
heparin
mgml
cell
put
contact
niv
h
number
viral
rna
n
gene
copi
determin
rtqpcr
spr
analysi
niv
pseudoparticl
bind
hpactiv
surfac
absenc
presenc
solubl
heparin
gml
gml
e
spr
analysi
bind
niv
pseudoparticl
hpactiv
sensor
chip
preincub
either
pb
gml
solubl
heparin
csa
csc
ds
f
spr
analysi
bind
niv
pseudoparticl
express
either
nivg
nivf
protein
hpactiv
sensor
chip
bind
respons
ru
record
function
time
remov
background
provid
nonpseudotyp
particl
result
present
averag
separ
experi
standard
error
mean
reflect
statist
signific
bind
nivg
hp
p
onesampl
test
prevent
bind
niv
cell
measur
cellassoci
viral
rna
residu
bind
hsdefect
cho
cell
line
remain
unaffect
fig
result
indic
abil
heparin
elut
viral
particl
cell
surfac
hs
competit
accordingli
solubl
heparin
abl
compet
inhibit
nivpseudotyp
bind
immobil
hp
hs
spr
fig
data
shown
reduct
observ
gml
gml
heparin
respect
notabl
gag
found
cell
surfac
proteoglycan
chondroitin
sulfat
csa
csc
ds
devoid
inhibit
properti
fig
reveal
specif
inhibit
niv
bind
hs
heparin
final
determin
two
niv
membran
glycoprotein
f
g
respons
bind
heparin
analyz
hp
bind
pseudotyp
niv
express
either
nivf
g
spr
fig
significantli
bind
obtain
nivg
nivf
fig
result
confirm
use
hela
cell
transfect
either
nivg
f
data
shown
conclud
result
niv
transinfect
requir
bind
cell
surfac
hs
via
nivg
process
inhibit
competit
heparin
hs
facilit
henipaviru
infect
ci
gag
may
play
multipl
role
viral
infect
next
investig
whether
hs
could
directli
involv
henipaviru
infect
ci
addit
role
transinfect
permiss
vero
cell
treat
heparinas
remov
cell
surfac
hs
prior
infect
niv
result
modest
signific
reduct
number
infect
cell
day
postinfect
fig
furthermor
inhibit
hs
sulfat
vero
cell
treatment
sodium
chlorat
significantli
reduc
infect
niv
fig
hev
fig
latter
much
sensit
sodium
chlorat
pretreat
former
obtain
result
therefor
suggest
hs
sulfat
statu
determin
viru
attach
cell
subsequ
infect
test
whether
solubl
gag
could
interfer
henipaviru
infect
ci
heparin
pretreat
vero
cell
reproduc
reduc
number
cell
infect
either
niv
hev
fig
furthermor
pretreat
either
cell
viru
effici
even
low
concentr
gml
fig
distinguish
contribut
heparinmedi
inhibit
nivg
bind
cell
surfac
hs
bind
entri
receptor
hsneg
cell
stabli
express
either
pretreat
gml
heparin
infect
niv
fig
heparin
treatment
modestli
significantli
reduc
percentag
infect
cell
cell
line
indic
molecul
may
also
directli
inhibit
delay
bind
niv
entri
receptor
effect
may
consequ
direct
heparin
bind
andor
recent
suggest
inde
spr
analysi
suggest
cell
bound
heparin
contrast
nontransfect
cell
fig
proport
level
express
transcript
fig
accordingli
solubl
recombin
bound
heparin
spr
assay
well
fig
fit
langmuir
bind
model
yield
k
nm
mean
standard
deviat
sd
interact
addit
spr
analysi
show
interact
hs
heparin
cs
data
shown
thu
abil
compet
hs
bind
nivg
interfer
receptor
heparin
restrict
transand
cisinfect
henipaviru
heparin
treatment
restrict
nipah
viru
infect
anim
well
known
anticoagul
properti
heparin
bind
activ
antithrombin
iii
atiii
specif
pentasaccharid
sequenc
test
antivir
effect
heparin
niv
infect
vivo
avoid
potenti
hemorrhag
complic
produc
heparin
lack
anticoagul
activ
use
period
oxid
poheparin
alter
integr
atiiibind
pentasaccharid
motif
sinc
poheparin
inhibit
lymphocytemedi
niv
transinfect
vitro
similarli
heparin
fig
test
antivir
properti
golden
hamster
model
niv
infect
close
reproduc
niv
pathogenesi
seen
human
nontreat
anim
succumb
infect
less
day
surviv
poheparintr
group
increas
moder
p
fig
thu
suggest
biolog
relev
nivh
interact
reveal
potenti
antivir
properti
heparinlik
molecul
vivo
rapid
dissemin
nipah
viru
hendra
viru
infect
host
may
play
critic
role
high
pathogen
henipavirus
previou
work
demonstr
human
peripher
blood
lymphocyt
permiss
niv
infect
could
captur
viru
transmit
suscept
target
cell
tran
contrast
human
lymphocyt
specif
subset
porcin
lymphocyt
could
infect
niv
thu
particip
transmiss
viru
swine
host
also
ci
low
level
viral
replic
detect
human
dendrit
cell
suggest
cell
popul
could
contribut
transmiss
niv
ci
tran
recent
transinfect
pathway
dendrit
cell
demonstr
henipavirus
howev
molecular
mechan
niv
transinfect
mediat
lymphocyt
express
remain
obscur
report
reveal
hs
cell
surfac
attach
receptor
niv
hev
implic
transinfect
properti
human
leukocyt
well
henipaviru
infect
ci
hs
shown
bind
mani
differ
virus
interact
either
one
viral
glycoprotein
interact
hs
envelop
glycoprotein
vaccinia
viru
protein
demonstr
furthermor
hs
bind
measl
viru
hemagglutinin
h
fusion
f
protein
respiratori
syncyti
viru
rsv
human
metapneumoviru
case
bovin
rsv
canin
distemp
viru
h
f
seem
interact
hs
result
suggest
nivg
interact
hs
although
vsvg
protein
shown
interact
hs
spr
analysi
indic
bind
nivg
hs
higher
affin
studi
use
recombin
solubl
viral
g
protein
give
better
insight
biochem
characterist
interact
identifi
bind
site
ligand
hs
previous
suggest
captur
protect
transmit
human
tcell
lymphotrop
viru
type
tran
similarli
shown
sulfat
gag
cs
ds
inact
impli
structur
featur
beyond
charg
densiti
polysaccharid
backbon
could
import
activ
implic
differ
hsbind
site
may
involv
shown
recent
papillomaviru
sequenti
engag
three
differ
hsbind
site
lead
viru
attach
interact
receptor
entri
cell
likewis
hs
stabil
varicellazost
viru
make
access
bind
entri
receptor
thu
similar
role
viral
infect
hs
could
improv
contact
henipaviru
host
cell
help
viru
reach
cellular
receptor
summar
schemat
fig
observ
heparin
inhibit
henipaviru
transinfect
vitro
owe
capac
bind
multipl
cell
surfac
protein
via
neg
charg
sulfat
group
heparin
could
prevent
henipaviru
attach
cell
surfac
hs
sulfat
hs
could
also
bind
virus
higher
affin
hs
thu
act
effici
competit
inhibitor
viru
bind
furthermor
heparin
significantli
reduc
direct
viru
infect
ci
addit
affect
infect
tran
effect
may
also
result
interact
heparin
henipaviru
receptor
evidenc
spr
agreement
recent
report
result
allow
us
propos
model
role
hs
henipaviru
bind
entri
possibl
interfer
heparin
viral
infect
fig
addit
inhibit
henipaviru
infect
bind
either
viral
g
glycoprotein
viral
entri
receptor
heparin
may
significantli
limit
viru
spread
within
organ
block
bind
attach
receptor
hs
consecut
transinfect
permiss
cell
mechan
heparin
molecul
devoid
anticoagul
properti
restrain
viru
infect
vivo
like
depend
combin
differ
biolog
activ
addit
affect
henipaviru
infect
ci
tran
heparin
could
constrain
inflamm
consequ
tissu
damag
bind
variou
inflammatori
molecul
inde
heparin
hs
bind
import
immunoregulatori
molecul
chemokin
strongli
upregul
niv
infect
moreov
heparin
heavili
sulfat
electroneg
molecul
might
enhanc
antiadhes
properti
endothelium
leukocyt
effect
may
reli
abil
heparin
bind
directli
sever
adhes
molecul
express
inflamm
includ
lselectin
pselectin
final
heparinlik
deriv
stabil
endothelium
help
block
passag
humor
cellular
immun
factor
well
virus
bloodbrain
barrier
process
may
also
contribut
antivir
effect
observ
vivo
experi
togeth
provid
proof
concept
develop
antivir
approach
heparinmedi
inhibit
henipaviru
infect
vitro
vivo
highlight
antivir
potenti
gag
well
toler
alreadi
use
clinic
environ
anticoagul
year
inde
heparin
treatment
reduc
niv
infect
hamster
anim
model
thu
open
interest
therapeut
perspect
complement
treatment
highli
lethal
infect
addit
acut
natur
henipaviru
infect
make
prone
regulatori
action
heparin
compar
chronic
infect
includ
hiv
htlv
heparin
show
vitro
antivir
activ
hs
mimet
alreadi
shown
signific
benefici
effect
vivo
outcom
dengu
viru
encephalit
flaviviru
infect
use
deriv
mimic
heparinh
structur
synthet
antilipopolysaccharid
peptid
bind
hs
moieti
cell
surfac
polyanion
compound
longer
halfliv
vivo
devoid
anticoagul
activ
potenti
higher
affin
henipaviru
gprotein
may
improv
therapeut
effect
altogeth
studi
demonstr
previous
unrecogn
hshenipaviru
interact
involv
niv
hev
infect
dissemin
within
host
may
allow
henipavirus
bind
differ
circul
cell
use
transport
effici
spread
within
host
organ
target
cell
allow
accumul
surfac
enhanc
efficaci
infect
ci
result
reveal
heparan
sulfat
potenti
therapeut
target
develop
novel
approach
highli
lethal
infect
context
heparin
deriv
may
use
metaphylaxi
approach
virusexpos
potenti
infect
anim
appear
clinic
symptom
regular
hendra
equin
epizoot
australia
ethic
statement
venou
blood
anonym
healthi
human
volunt
obtain
blood
transfus
centr
etabliss
francai
du
sang
lyon
franc
accord
guidelin
inform
written
consent
volunt
anim
handl
strict
accord
good
anim
practic
defin
french
nation
charter
ethic
anim
experi
effort
made
minim
suffer
anim
work
approv
region
ethic
committe
ceccapp
experi
perform
inserm
jean
laboratori
lyon
franc
french
anim
regul
commite
number
cell
cultur
cho
cell
line
cho
cell
stabli
transfect
human
gener
provid
b
lee
ucla
unit
state
maintain
medium
invitrogen
supplement
fetal
calf
serum
fc
uml
penicillin
mg
streptomycin
mm
hepe
mm
lglutamin
co
vero
hsdefici
cell
cho
cho
cho
cell
hela
cell
stabl
transfect
hela
cell
phcmvnipahgneo
phcmvnipahfneo
express
nivg
f
protein
respect
helag
helaf
maintain
dulbecco
modifi
eagl
medium
dmem
invitrogen
supplement
describ
human
peripher
blood
obtain
differ
healthi
donor
blood
transfus
centr
lyon
franc
peripher
blood
mononuclear
cell
isol
densiti
ficollhypaqu
gradient
centrifug
centrifug
percol
gradient
pharmacia
fine
chemic
min
g
pbl
recov
highdens
fraction
spr
analysi
cell
detach
versen
treatment
wash
twice
hbsp
buffer
mm
hepe
mm
nacl
surfact
ph
viru
infect
titrat
nipah
viru
isol
genbank
access
number
recombin
niv
express
enhanc
green
fluoresc
protein
hendra
viru
australia
obtain
porton
laboratori
unit
kingdom
prepar
cell
describ
previous
infect
viru
use
inserm
jean
laboratori
lyon
franc
cell
infect
multipl
infect
moi
h
wash
twice
observ
invert
andor
fluoresc
microscopi
daili
harvest
rna
isol
use
transinfect
assay
indic
time
postinfect
l
cell
cultur
supernat
collect
frozen
prior
viral
titrat
viral
titrat
perform
plaqu
assay
detail
elsewher
viral
infect
level
cocultur
leukocyt
cho
cell
vero
cell
determin
use
previous
describ
infecti
center
assay
plate
min
formaldehyd
fixat
crystal
violet
stain
altern
heparinmedi
inhibit
assay
titrat
directli
perform
plaqu
assay
use
vero
cell
cell
monolay
pseudotyp
viral
particl
contain
either
nivg
andor
f
control
vsvg
produc
use
friend
murin
leukemia
viru
mlv
particl
cell
describ
previous
treatment
cell
sodium
chlorat
vero
cell
monolay
grown
confluenc
maintain
dmem
supplement
fc
sodium
chlorat
naclo
mm
h
inhibit
hs
sulfat
cell
rapid
turnov
proteoglycan
cell
requir
prolong
incub
naclo
cell
detach
use
edta
distribut
new
tissu
cultur
plate
grown
confluenc
presenc
rang
concentr
naclo
infect
either
niv
hev
pfuwel
follow
h
incub
cmcdmem
supplement
fc
naclo
viru
titrat
use
crystal
violet
stain
transinfect
assay
cell
put
contact
viru
moi
h
co
two
wash
phosphatebuff
salin
pb
cell
cultur
h
collect
wash
serial
dilut
ad
cell
monolay
vero
cell
determin
cellassoci
infecti
niv
infecti
center
assay
describ
previous
experi
cell
incub
h
uml
heparinas
sigma
wash
time
contact
niv
treatment
heparin
porcin
intestin
mucosa
sigma
either
cell
viru
pseudotyp
viral
particl
perform
min
heparin
pretreat
experi
incub
heparin
cell
thoroughli
wash
ad
viru
heparin
posttreat
experi
nivresist
cell
initi
put
contact
either
niv
hev
h
incub
heparin
afterward
min
wash
analyz
transinfect
assay
describ
sprbase
bind
assay
spr
experi
perform
biacor
x
apparatu
analysi
cell
pseudotyp
viral
particl
biacor
apparatu
pseudotyp
viral
particl
recombin
use
pseudotyp
viru
recombin
cell
sensor
chip
hbsp
buffer
hs
celsu
cincinnati
oh
unit
state
hp
sigma
ds
sigma
biotinyl
immobil
biacor
sensor
chip
describ
briefli
two
flow
cell
activ
mix
nethyln
diethylaminopropyl
carbodiimid
edc
nhydroxysuccinimid
nh
streptavidin
gml
mm
acet
buffer
ph
inject
activ
flow
cell
obtain
immobil
level
respons
unit
ru
one
flow
cell
serv
neg
control
biotinyl
hp
hs
ds
inject
flow
cell
obtain
suitabl
immobil
level
ru
recombin
human
fc
pseudotyp
viral
particl
analysi
ru
cell
interact
assay
perform
flow
rate
lmin
involv
inject
sampl
hp
negativecontrol
surfac
follow
wash
step
hbsp
buffer
allow
dissoci
complex
form
end
cycl
gag
surfac
regener
sequenti
inject
sd
min
nacl
min
typic
sampl
concentr
use
gml
recombin
human
fc
r
system
particlesml
pseudotyp
viral
particl
cellsml
hela
cell
transfect
sensorgram
shown
correspond
onlin
subtract
negativecontrol
signal
gag
surfac
signal
competit
assay
perform
preincub
niv
pseudoparticl
gag
gml
final
concentr
min
prior
inject
rna
isol
rtqpcr
rna
isol
cell
plasma
use
rneasi
minikit
qiagen
rlt
buffer
accord
manufactur
instruct
revers
transcript
rt
perform
g
total
rna
use
oligo
dt
random
hexam
oligonucleotid
primer
iscript
cdna
synthesi
kit
biorad
run
biometra
tgradient
pcr
devic
cdna
dilut
quantit
pcr
qpcr
perform
cdna
sampl
use
platinum
sybr
green
qpcr
supermixudg
rox
kit
invitrogen
qpcr
run
stepon
plu
pcr
system
appli
biosystem
follow
min
cycl
min
follow
melt
curv
interv
sampl
run
duplic
result
analyz
use
stepon
softwar
glyceraldehyd
dehydrogenas
gapdh
gene
use
housekeep
gene
normal
sampl
gapdh
standard
refer
correspond
gene
includ
run
check
rna
integr
rna
load
interpcr
variat
normal
result
express
number
mrna
copi
gene
interest
per
microgram
analyz
rna
calcul
done
use
model
experi
perform
accord
miqe
guidelin
primer
use
includ
follow
niv
n
forward
ggcaggattcttcgcaaccatc
revers
ggctcttg
ggccaatttctctg
murin
gapdh
forward
gcatggccttccgt
gtcc
revers
tgtcatcatacttggcaggtttct
forward
caagttctgctggatcaa
revers
gatgttgttccccg
aatg
forward
atggaaagagaccgaggg
revers
ga
ggttgcattgctggtg
product
heparin
devoid
anticoagul
activ
poheparin
elimin
anticoagul
properti
heparin
treat
period
previous
describ
briefli
mg
heparin
porcin
intestin
usp
unitsmg
sigma
dissolv
l
naio
sodium
acet
buffer
ph
stir
day
unreact
naio
neutral
addit
glycerol
l
dialyz
h
lyophil
sampl
resuspend
l
nabh
ammonium
bicarbon
incub
h
acidif
glacial
acet
acid
elimin
remain
nabh
reaction
mixtur
neutral
addit
naoh
dialyz
water
lyophil
infect
hamster
eightweekold
golden
hamster
mesocricetu
auratu
janvier
franc
anesthet
infect
intraperiton
ml
contain
niv
lethal
dose
ld
preincub
heparin
mgml
min
group
anim
treat
daili
subcutan
poheparin
mgkg
bodi
weight
day
start
day
infect
anim
follow
daili
week
statist
analysi
data
express
mean
sd
percentag
surviv
statist
analys
perform
use
mannwhitney
u
test
onesampl
test
mantelcox
test
within
graphpad
softwar
